Research Paper Volume 11, Issue 9 pp 2874—2888
Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
Figure 4. Left. Waterfall plots showing the log2 fold chance of circulating Hcy and correlation with treatment outcomes. Right. Violin plots depicting the log2 fold chance of circulating Hcy in each treatment arm categorized by treatment outcomes. (pCR: pathological complete response; QT: chemotherapy; Tzb: trastuzumab; MET: metformin; p-values by Wilcoxon signed-ranked test).